5
The need for calcium supplements is a growing problem arising out of improper nutrition
and limited outdoor activity in urban India. To service this growing need, your Company
has launched CCM and this brand has rapidly become the 2
nd
largest product in the
therapeutic area (source: IMS MAT DEC 13). It has also in the current year become one
of the top three hundred products in the Pharmaceutical Industry in India. To help patients
afflicted by allergic rhinitis, your Company has launched Avamys, a leading health solution
from GSK plc’s portfolio. It has been well received by the patients and the prescribers and
has rapidly become the 2
nd
largest brand in its relevant market in the first year of introduction
(source: IMS TSA MAT DEC 13).
Serious fungal infections in the intensive care setting are a barrier to treatment of patients.
Mycamine which was launched by your Company a few years ago has become the
2
nd
largest product in this therapeutic area among twenty six offerings with competitive increase
in market share. (source: IMS TSA MAT DEC 13).
Mass Markets service the largest patient pool of your Company. New offerings like
Uricostat in the treatment of gout, Cefspan, an anti-infective, Lilo, a statin for lowering
blood cholesterol and the nutritional range (being marketed by your Company on behalf
of GSK’s Consumer business) have all recorded significant acceptance by the patients
and the prescribers alike. To meet the increasing healthcare needs of rural India, the
rural team “Reach” continued to expand its patient base as the portfolio of products
offered to patients in these geographies continued to expand. This team now services six
thousand villages and twenty thousand healthcare professionals. Your Company’s efforts at
increasing the knowledge base of healthcare professionals in these geographies continued
and 140 programs were conducted for the benefit of healthcare professionals in these
geographies. Calpol continues to remain the most prescribed brand in the Indian
Pharmaceutical Industry (source: IMS TSA JAN 14).
In the area of preventive healthcare, GSK Vaccines became the leading company in the private
market for vaccines in India. The recently introduced vaccine for pneumococcal conjugate
disease, Synflorix, became the biggest brand in the vaccine portfolio of your Company in the
second year of its launch. The efforts of your Company in raising awareness about vaccines
preventable diseases continued with increasing fervour.
Exports recorded a sales turnover of Rs. 9.5 crores comprising of both Bulk Drugs and
Formulations. Exports of Bulk Drugs were to major markets like Japan, France, Jordan, and
Sri Lanka.
(c) Opportunities, risk, concerns and threats
The Indian Government notified the National Pharmaceutical Policy and the new Drugs (Prices
Control) Order, 2013 was implemented in May 2013. The new DPCO expanded the list of
drugs from 74 to 348 (approximate 650 formulations got added). It brought about challenges
for the Pharmaceutical Industry with regard to labeling of the new notified prices on all the
products available in the market within a period of 45 days from the date of the Notification
coupled with challenges with regard to recall and storage of recalled drugs. This has impacted
sales in the second half of the year.
However, some of the stakeholders continued to oppose the new DPCO and a petition is
pending before the Supreme Court. Any changes to the new DPCO would have an impact on
the working of your Company.
Your Company has recently made an announcement with regard to its intent of creating
a new Greenfield site with additional manufacturing capability, with an estimated investment of
Rs. 860 crores. This new facility will substantially increase the capacity of manufacturing base
and enable us to bring more medicines to the people of India.
(d) Regulatory Affairs, Clinical Research, Medical Affairs and Medical Governance
During the year under review, in order to support the commercial availability of new drugs that
would benefit and improve the quality of life of Indian patients suffering from various diseases,
your Company submitted several applications for New Products in India to the CDSCO
(Central Drugs Standard Control Organization), Ministry of Health and Family Welfare,
Government of India. After a thorough review of these applications, your Company has
received approval for some of these products from CDSCO, which will enable timely access
to new and innovative therapeutic options to patients in our country.
